Innoviva (NASDAQ: INVA) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK.
Feb 9, 2017 at 5:00 PM ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.
Sign up to receive important email alerts & updates from Innoviva.Sign up now
Innoviva Investor Relations & Media
For business development inquiries,
please contact firstname.lastname@example.org.